Guided Therapeutics

Guided Therapeutics FCF Margin

The Free Cash Flow Margin of Guided Therapeutics (GTHP) as of Oct 18, 2026 is -139.50 %. In the previous year, Free Cash Flow Margin was -15,985.71 % — a change of -99.13% (higher).

FCF Margin

-139.50 %

YoY

-99.13%

Last updated:

Free Cash Flow Margin of Guided Therapeutics is 2025 -139.50 % . Free Cash Flow Margin of Guided Therapeutics was 2024 -15,985.71 % . It decreases by -99.13% higher compared to the previous year.

The Guided Therapeutics FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-2,396.49 USD
Jan 1, 2019
-2,241.67 USD
Jan 1, 2020
-1,839.22 USD
Jan 1, 2021
-1,982.72 USD
Jan 1, 2022
-11,615.38 USD
Jan 1, 2023
-1,781.63 USD
Jan 1, 2024
-15,985.71 USD
Jan 1, 2025
-139.50 USD
The Guided Therapeutics FCF Margin history
YEARFCF MarginYoY
-139.50 %-99.13%
-15,985.71 %+797.25%
-1,781.63 %-84.66%
-11,615.38 %+485.83%
-1,982.72 %+7.80%
-1,839.22 %-17.95%
-2,241.67 %-6.46%
-2,396.49 %+410.69%
-469.26 %+59.03%
-295.08 %-55.56%
-663.93 %-15.33%
-784.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guided Therapeutics Stock analysis

What does Guided Therapeutics do? Guided Therapeutics Inc, with ticker GTHP and ISIN US40171F5017, is a health care company headquartered in Norcross, Georgia. The company has 6 employees and went public on July 1, 1997. Guided Therapeutics focuses on developing medical devices, particularly utilizing biophotonic technology for cancer detection. The company's primary product is the LuViva Advanced Cervical Scan, a non-invasive device designed to detect cervical cancer and precancers. The LuViva device scans the cervix with light and analyzes the reflected and fluorescent light to provide results at the point of care. It serves as an alternative to conventional cervical cancer screening methods, targeting two main applications: as a screening tool and as a triage method for traditional screening processes. The company develops prototypes and conducts limited clinical studies using its biophotonic technology, which is central to its approach for detecting esophageal cancer. Guided Therapeutics operates within the health care sector and industry, with its website at https://www.guidedinc.com/. The company's current operational focus is on the development and marketing of the LuViva device, though it has also explored applications in esophageal cancer detection through biophotonic technology. Guided Therapeutics has a small workforce of six full-time employees, reflecting its current scale of operations. Guided Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guided Therapeutics stock

Free Cash Flow Margin of Guided Therapeutics is -139.50 % in 2025.

Free Cash Flow Margin of Guided Therapeutics changed from -15,985.71 % to -139.50 %, representing a -99.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Guided Therapeutics since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Guided Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Guided Therapeutics

All Key Metrics — Guided Therapeutics